Literature DB >> 98142

Experience with large volume plasmapheresis in malignant paraproteinaemia and immune disorders.

J P Isbister, J C Biggs, R Penny.   

Abstract

Clinical experience with large volume plasmapheresis in a wide range of malignant and immune disorders is described. An average of 4 litres of plasma was exchanged for various colloid and electrolyte solutions. Patient tolerance was good but close medical and nursing supervision in monitoring fluid balance and adverse reactions to replacement fluids is necessary. Plasmapheresis has been established to be of benefit in immunoproliferative diseases when complicated by hyperviscosity, and may also have a place in other cases with haemostatic or renal impairment. Autoantibodies, alloantibodies and immune complexes can be removed by plasmapheresis, but the effect is usually transient and the procedure should be combined with immunosuppressive therapy in most cases. The removal of blocking factors in disseminated malignant melanoma is an experimental procedure at present, but initial results have been encouraging.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 98142     DOI: 10.1111/j.1445-5994.1978.tb04503.x

Source DB:  PubMed          Journal:  Aust N Z J Med        ISSN: 0004-8291


  5 in total

Review 1.  Plasmapheresis in paraproteinemia.

Authors:  H H Euler; N Schmitz; H Löffler
Journal:  Blut       Date:  1985-06

2.  Suitable hollow fibre immunobioreactors for specific ex vivo removal of antibodies and antigens from plasma.

Authors:  C Larue; V Gueraud; C Rivat
Journal:  Clin Exp Immunol       Date:  1985-10       Impact factor: 4.330

Review 3.  Potential for plasma exchange in children.

Authors:  E A Robinson
Journal:  Arch Dis Child       Date:  1982-04       Impact factor: 3.791

4.  Plasmapheresis therapy in a patient with multiple myeloma.

Authors:  M Paul; F Walker; R A Bear
Journal:  Can Med Assoc J       Date:  1982-11-15       Impact factor: 8.262

5.  Extracorporeal immunoadsorption of myeloma IgG and autoimmune antibodies: a clinically feasible modality of treatment.

Authors:  P K Ray; E Besa; A Idiculla; J E Rhoads; J G Bassett; D R Cooper
Journal:  Clin Exp Immunol       Date:  1980-11       Impact factor: 4.330

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.